Program Offering and Eligibility

With the ENSPRYNG Co-pay Program, eligible, commercially insured patients pay as little as $5 per 30-day supply of ENSPRYNG. The program covers the rest of the patient's out-of-pocket costs, up to $20,000 in assistance per calendar year.

There are no income requirements for the ENSPRYNG Co-pay Program.

  • Have been prescribed ENSPRYNG for an FDA-approved indication
  • Are 18 years of age or older, or have a caregiver or have a legally authorized person to manage the patient's co-pay assistance
  • Have commercial (private or non-governmental) insurance.* This includes plans available through state and federal health insurance exchanges
  • Reside and receive treatment in the United States or U.S. Territories
  • Are not receiving assistance through the Genentech Patient Foundation or any other charitable organization for the same expenses covered by the program
  • Are not a government beneficiary and/or participant in a federal or state-funded health insurance program (e.g., Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD, TRICARE)


*Commercial insurance includes plans you receive from your job or plans from the Health Insurance Marketplace. Government programs like Medicare and Medicaid are not commercial insurance.

If a patient is not eligible for the ENSPRYNG Co-pay Program, there may be other options for co-pay assistance. Call (844) 677-7964 or visit to learn more.

Indication and Important Safety Information

ENSPRYNG Important Safety Information


ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.


ENSPRYNG is contraindicated in patients with a known hypersensitivity to satralizumab or any of the inactive ingredients, an active hepatitis B infection, or active or untreated latent tuberculosis.

Warnings and Precautions

Delay ENSPRYNG administration in patients with an active infection until the infection is resolved. Vaccination with live or live attenuated vaccines is not recommended during treatment.

Elevated Liver Enzymes
Monitor ALT and AST levels during treatment; interruption of ENSPRYNG may be required.

Decreased Neutrophil Counts
Monitor neutrophils during treatment.

Most Common Adverse Reactions

The most common adverse reactions (≥15% in either trial) were nasopharyngitis (31%), headache (27%), upper respiratory tract infection (19%), rash (17%), arthralgia (17%), extremity pain (15%), gastritis (15%), fatigue (15%), and nausea (15%).

You may report side effects to the FDA at 1-800-FDA-1088 or You may also report side effects to Genentech at 1-888-835-2555.

For additional safety information, please see the full Prescribing Information and Medication Guide.